Outlook Therapeutics Inc [OTLK] stock prices are up 7.16% to $5.69 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The OTLK shares have gain 11.79% over the last week, with a monthly amount drifted -5.17%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Outlook Therapeutics Inc [NASDAQ: OTLK] stock has seen the most recent analyst activity on March 27, 2024, when BTIG Research upgraded its rating to a Buy but kept the price target unchanged to $50 for it. Previously, Chardan Capital Markets upgraded its rating to Buy on February 15, 2024, and kept the price target unchanged to $3. On January 25, 2024, upgrade upgraded it’s rating to Buy. CapitalOne upgraded its rating to a Overweight but stick to its price target of $5 on December 27, 2023. H.C. Wainwright downgraded its rating to a Neutral and reduced its price target to $1 on August 31, 2023. Chardan Capital Markets downgraded its rating to Neutral for this stock on August 31, 2023. In a note dated August 30, 2023, Guggenheim downgraded an Neutral rating on this stock.
The stock price of Outlook Therapeutics Inc [OTLK] has been fluctuating between $4.61 and $18.00 over the past year. Outlook Therapeutics Inc [NASDAQ: OTLK] shares were valued at $5.69 at the most recent close of the market.
Analyzing the OTLK fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -2.0, Equity is 1.47 and Total Capital is -13.51. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-0.39.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 5.46 points at the first support level, and at 5.24 for the second support level. However, for the 1st resistance point, the stock is sitting at 5.83, and for the 2nd resistance point, it is at 5.98.
Ratios To Look Out For
It’s worth pointing out that Outlook Therapeutics Inc [NASDAQ:OTLK]’s Current Ratio is 1.07. In addition, the Quick Ratio stands at 1.07 and the Cash Ratio stands at 0.75.
Transactions by insiders
Recent insider trading involved KENYON LAWRENCE A, Chief Financial Officer, that happened on Sep 26 ’24 when 5000.0 shares were purchased. Director, Haddadin Yezan Munther completed a deal on Mar 28 ’24 to buy 1882.0 shares. Meanwhile, CHIEF COMMERCIAL OFFICER Evanson Jeff bought 62484.0 shares on Mar 07 ’24.
